United States | December 23, 2025 — Fulgent Genetics has entered into a definitive agreement to acquire specific assets of Bako Diagnostics and to acquire StrataDx, two U.S.-based diagnostic laboratories, for a combined purchase price of approximately $55.5 million. The transaction, expected to close in the first half of 2026 subject to regulatory approvals and customary conditions, marks a strategic expansion of Fulgent’s laboratory services and pathology diagnostics footprint.
Science Significance
From a scientific and technical perspective, the acquisition meaningfully expands Fulgent’s diagnostic testing capabilities across anatomic pathology, molecular diagnostics, and dermatopathology. Bako Diagnostics brings a broad testing menu, including polymerase chain reaction (PCR) assays, molecular genetic testing, and specialized immunohistochemical evaluations for peripheral neuropathy. StrataDx adds dermatopathology expertise supported by advanced laboratory workflows. Combined with Fulgent’s ongoing investments in AI-enabled digital pathology and image management platforms, the transaction strengthens analytical depth, improves diagnostic accuracy, and supports faster turnaround times—key drivers of quality in modern laboratory medicine.
Regulatory Significance
Regulatory compliance remains central to the transaction’s value. StrataDx operates as a CLIA-certified and state-licensed laboratory, underscoring adherence to Clinical Laboratory Improvement Amendments (CLIA) standards and state regulatory oversight. Integration of Bako and StrataDx will require harmonization of quality management systems, validation protocols, data integrity controls, and post-acquisition audits to maintain compliance across expanded operations. For cGxP stakeholders, the deal highlights the importance of regulatory due diligence, inspection readiness, and consistent quality systems when consolidating regulated diagnostic assets under a single corporate structure.
Business Significance
Advertisement
Strategically, the acquisition is designed to bolster Fulgent’s lab services business by adding new products, expanding its national client base, and nearly doubling the size of its pathology-focused sales force. The purchase will be funded entirely from cash on hand, reflecting balance-sheet strength and disciplined capital deployment. By combining Bako’s and StrataDx’s offerings with Fulgent’s existing portfolio, the company aims to achieve operational synergies, scale efficiencies, and revenue diversification. The deal also deepens Fulgent’s presence in high-demand pathology markets, positioning the company for sustained growth amid increasing demand for specialized diagnostics.
Patients’ Significance
At a policy level, the acquisition reflects ongoing consolidation within the U.S. diagnostics and laboratory services sector, driven by the need for scale, technological investment, and regulatory compliance. Policymakers and regulators continue to emphasize quality, access, and data integrity in laboratory medicine, particularly as advanced diagnostics become integral to personalized care. Transactions like this underscore the role of capital investment and operational integration in sustaining compliant, resilient diagnostic infrastructure while meeting growing healthcare demand.
Policy Significance
At a policy level, the acquisition reflects ongoing consolidation within the U.S. diagnostics and laboratory services sector, driven by the need for scale, technological investment, and regulatory compliance. Policymakers and regulators continue to emphasize quality, access, and data integrity in laboratory medicine, particularly as advanced diagnostics become integral to personalized care. Transactions like this underscore the role of capital investment and operational integration in sustaining compliant, resilient diagnostic infrastructure while meeting growing healthcare demand.
With the planned acquisition of Bako Diagnostics assets and StrataDx, Fulgent Genetics is executing a strategic M&A move that strengthens its scientific capabilities, regulatory footprint, and commercial reach in pathology and molecular diagnostics. The transaction exemplifies how regulated diagnostics consolidation, when aligned with robust quality systems and technological innovation, can drive value across the healthcare ecosystem—making it a noteworthy development for cGxP.wire readers tracking compliance, quality, and industry transformation.
Source: Fulgent Genetics press release
